P/E ratio for Pieris Pharmaceuticals (PIRS)
P/E ratio as of June 2024 (TTM): -25.6
According to Pieris Pharmaceuticals's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -25.6216. At the end of 2022 the company had a P/E ratio of -2.31.
P/E ratio history for Pieris Pharmaceuticals from 2015 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | -2.31 | -57.81% |
| 2021 | -5.48 | 49.01% |
| 2020 | -3.68 | -44.14% |
| 2019 | -6.58 | 22.17% |
| 2018 | -5.39 | -71.46% |
| 2017 | -18.9 | 625.44% |
| 2016 | -2.60 | -52.28% |
| 2015 | -5.45 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 Gilead Sciences GILD | 15.7 | -161.19% | 🇺🇸 USA |
 Flexion Therapeutics
FLXN | N/A | N/A | 🇺🇸 USA |
 Aeterna Zentaris AEZS | -0.9764 | -96.19% | 🇺🇸 USA |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.